Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3002 in Moderate-to-Severe Atopic Dermatitis (Phase II)
CTR20260089Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3002 in atopic dermatitis (AD), sponsored by InnoCare Pharma. Started Feb 2026; status: active.
02
Drugs
IBI3002
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20260089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260089.